NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.3 Anti-lymphocyte monoclonal antibodies > Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia - NICE TAG TA343

Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia - NICE TAG TA343

1.1 Obinutuzumab, in combination with chlorambucil, is recommended as an option for adults with untreated chronic lymphocytic leukaemia who have comorbidities that make full‑dose fludarabine‑based therapy unsuitable for them, only if:

  • bendamustine‑based therapy is not suitable and

  • the company provides obinutuzumab with the discount agreed in the patient access scheme.

1.2 People whose treatment with obinutuzumab is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

http://www.nice.org.uk/guidance/ta343

 

Site by Devopa
© Copyright 2020 NHS. All rights reserved.